艾伯维 2026年季度报告

(Mark One)☒ QUARTERLY REPORT PURSUANT TO SECTION13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended March 31, 2026 OR TRANSITION REPORT PURSUANT TO SECTION13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934 AbbVie Inc. (Exact name of registrant as specified in its charter) 32-0375147 Delaware (State or other jurisdiction of incorporation or organization) (I.R.S. employer identification number) 1 North Waukegan RoadNorth Chicago,Illinois 60064-6400 Telephone:(847) 932-7900 Indicate by check mark whether the registrant (1)hasfiled all reports required to befiled by Section13 or 15(d)of the Securities Exchange Act of 1934 duringthe preceding 12 months (or for such shorter period that the registrant was required tofile such reports), and (2)has been subject to suchfiling requirementsfor the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule405 ofRegulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit suchfiles).Yes☒No☐ Indicate by check mark whether the registrant is a large acceleratedfiler, an acceleratedfiler, a non-acceleratedfiler, a smaller reporting company, or anemerging growth company. See the definitions of “large acceleratedfiler,” “acceleratedfiler,” “smaller reporting company,” and "emerging growth company"in Rule12b-2 of the Exchange Act. Accelerated Filer☐Smaller reporting company☐Emerging growth company☐ Large Accelerated Filer☒Non-Accelerated Filer☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new orrevisedfinancial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Exchange Act).Yes☐No☒ Securities registered pursuant to Section 12(b) of the Act: AbbVie Inc. and SubsidiariesTable of Contents Item 1.FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA1Item 2.MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS22Item 3.QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK31Item 4.CONTROLS AND PROCEDURES31 PARTII.OTHER INFORMATION Item 1.LEGAL PROCEEDINGS32Item 2.UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS32Item 5.OTHER ITEMS32Item 6.EXHIBITS33 AbbVie Inc. and SubsidiariesCondensed Consolidated Statements of Earnings (unaudited) The accompanying notes are an integral part of these condensed consolidatedfinancial statements. AbbVie Inc. and SubsidiariesNotes to Condensed Consolidated Financial Statements (unaudited) Note 1 Basis of Presentation Basis of Historical Presentation The unaudited interim condensed consolidatedfinancial statements of AbbVie Inc. (AbbVie or the company) have been prepared pursuant to therulesand regulations of the United States Securities and Exchange Commission. Accordingly, certain information and footnote disclosuresnormally included in annualfinancial statements prepared in accordance with generally accepted accounting principles in the United States(GAAP) have been omitted. These unaudited interim condensed consolidatedfinancial statements should be read in conjunction with thecompany’s audited consolidatedfinancial statements and notes included in the company’s Annual Report on Form10-K for the year endedDecember 31, 2025. It is management’s opinion that thesefinancial statements include all normal and recurring adjustments necessary for a fair presentation of thecompany’sfinancial position and operating results. Net revenues and net earnings for any interim period are not necessarily indicative of futureor annual results. Certain other reclassifications were made to conform the prior period interim condensed consolidatedfinancial statements tothe current period presentation. Recent Accounting Pronouncements Recent Accounting Pronouncements Not Yet Adopted ASU No. 2024-03 In November 2024, the Financial Accounting Standards Board (FASB) issuedAccounting Standards Update (ASU) No. 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40). The standard requires further disaggregation of relevantexpense captions in a separate note to thefinancial statements. The standard is effective for AbbVie starting in annual periods in 2027 andinterim periods beginning in 2028, with early adoption permitted. AbbVie is currently assessing the impact of adopting this guidance on itsconsolidatedfinancial statements. Depreciation expense was $188 million for the three months ended March 31, 2026 and $181 million for the three months ended March 31,2025. Note 3 Earnings Per Share AbbVie grants certain restricted stock units (RSUs) that are considered to be participating securities. Due to the presence of pa